Statistical Analysis of PML Incidences of Natalizumab-Treated Patients From 2009 to 2016: Outcomes After Introduction of the Stratify JCV® DxSelect™ Antibody Assay

Journal of NeuroVirology - United Kingdom
doi 10.1007/s13365-016-0482-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Immunological Markers for PML Prediction in MS Patients Treated With Natalizumab

Frontiers in Immunology
AllergyImmunology
2015English

PML Risk Stratification Using Anti-JCV Antibody Index and L-Selectin

Multiple Sclerosis
Neurology
2015English

PML-IRIS During Fingolimod Diagnosed After Natalizumab Discontinuation

Case Reports in Neurological Medicine
2014English

High-Frequency MRI Monitoring Should Be Performed in Natalizumab-Treated MS Patients With Higher Risk of PML – Commentary

Multiple Sclerosis
Neurology
2017English

Effectiveness Analysis Through Enzyme-Linked Immunosorbent Assay Examination of Antibody After Pandemic H1N1 2009 Influenza Vaccination

Journal of the Korean Geriatrics Society
2013English

Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML

Neurology
Neurology
2011English

Using the Kulldorff’s Scan Statistical Analysis to Detect Spatio-Temporal Clusters of Tuberculosis in Qinghai Province, China, 2009–2016

BMC Infectious Diseases
Infectious Diseases
2017English

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities

Multiple Sclerosis International
Neurology
2015English

An Introduction to Multivariate Statistical Analysis

Technometrics
ModelingApplied MathematicsStatisticsProbabilitySimulation
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy